{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:07:16Z","timestamp":1772809636354,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronavirus disease 2109 (COVID-19) vaccines have recently been approved to curb the global pandemic. The risk of allergic reactions to the vaccine polyethylene glycol (PEG) component has raised significant public concern. Desensitization is suggested in cases of vaccine related hypersensitivity reactions. After comprehensive literature review on the topic, our aim was to establish a safe and effective desensitization protocol for patients with suspected or confirmed immediate type hypersensitivity reactions to the COVID-19 vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were referred to the McGill University Health Center (MUHC) Allergy-Immunology department for clinical evaluation following a reported reaction to their first dose of Moderna\u00ae mRNA-1273 or Pfizer-BioNTech\u00ae BNT162b2 vaccines. They underwent skin prick testing (SPT) with higher and lower molecular weight (MW) PEG and polysorbate 80, as per published protocols. Their second dose was administered following a desensitization protocol consisting of multiple dose-administration steps followed by a 60-min observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among a cohort of 142 patients with an increased risk for allergic reactions to the COVID-19 vaccines, six individuals were selected to undergo desensitization. All were female with allergic background including chronic spontaneous urticaria, anaphylaxis to medications, and\/or vaccines. The main symptom after their first dose was difficulty swallowing with lightheadedness or immediate urticaria, angioedema, and\/or dizziness. Two patients had positive skin testing. One patient was on chronic antihistamines which resulted in an inconclusive PEG skin test and the skin testing was negative for the three other patients. During the desensitization, two patients reported cutaneous symptoms of an immediate reaction and were managed with antihistamines. One of these patients also complained of ear pressure and had a drop in her systolic blood pressure, treated with intravenous fluids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that some individuals with an immediate-type hypersensitivity reaction to their first dose of mRNA COVID-19 vaccine may safely receive their second dose using a desensitization protocol. The success of this desensitization protocol is a step forward in the fight against COVID-19, allowing more individuals to be immunized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2022.825164","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T23:45:15Z","timestamp":1643759115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose"],"prefix":"10.3389","volume":"3","author":[{"given":"Faisal","family":"AlMuhizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaonie","family":"Ton-Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Heise","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Ben-Shoshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghislaine A. C.","family":"Isabwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Copaescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"B1","unstructured":"WHO Coronavirus (COVID-19)2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100541","DOI":"10.1016\/j.waojou.2021.100541","article-title":"Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University Hospital","volume":"14","author":"Paoletti","year":"2021","journal-title":"World Allergy Organ J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2021.05.020","article-title":"Optimizing investigation of suspected allergy to polyethylene glycols","volume":"149","author":"Bruusgaard-Mouritsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jaci.2011.11.038","article-title":"Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis","volume":"129","author":"Fung","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B10","first-page":"527","article-title":"Administration of egg-derived vaccines in patients with history of egg sensitivity","volume":"64","author":"Kletz","year":"1990","journal-title":"Ann Allergy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1710-1492-8-2","article-title":"No systemic reactions to influenza vaccination in egg-sensitized tertiary-care pediatric patients","volume":"8","author":"Upton","year":"2012","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.anai.2018.02.007","article-title":"Safe and effective intradermal influenza vaccine desensitization for delayed influenza vaccine allergy","volume":"120","author":"Kanaoka","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B13","first-page":"25","article-title":"Measles, mumps, rubella vaccine administration in egg-sensitive children: systemic reactions during vaccine desensitization","volume":"72","author":"Trotter","year":"1994","journal-title":"Ann Allergy."},{"key":"B14","first-page":"336","article-title":"Diagnosis and \u201cdesensitization\u201d in tetanus vaccine hypersensitivity","volume":"69","author":"Carey","year":"1992","journal-title":"Ann Allergy."},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.arcped.2009.01.002","volume":"16","author":"Ponvert","year":"2009","journal-title":"Arch Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000346350","article-title":"Administration of yellow fever vaccine in patients with egg allergy","volume":"161","author":"Rutkowski","year":"2013","journal-title":"Int Arch Allergy Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0889-8561(03)00099-7","article-title":"Vaccine allergy: diagnosis and management","volume":"23","author":"Madaan","year":"2003","journal-title":"Immunol Allergy Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1016\/j.jaip.2021.06.025","article-title":"PEG\/polysorbate skin testing has no utility in the assessment of suspected allergic reactions to SARS-CoV-2 vaccines","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3308.e3","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.23822\/EurAnnACI.1764-1489.214","article-title":"Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG","volume":"53","author":"Radice","year":"2021","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1001\/jamainternmed.2021.3779","article-title":"Safety evaluation of the second dose of messenger RNA covid-19 vaccines in patients with immediate reactions to the first dose","volume":"181","author":"Krantz","year":"2021","journal-title":"JAMA Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e12044","DOI":"10.1002\/clt2.12044","article-title":"Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up","volume":"11","author":"Rasmussen","year":"2021","journal-title":"Clin Transl Allergy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1016\/j.jaip.2021.09.039","article-title":"Tolerability of polysorbate 80-containing COVID-19 vaccines in confirmed polyethylene glycol-allergic patients","volume":"9","author":"Ieven","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cea.14064","article-title":"The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients","volume":"52","author":"Sellaturay","year":"2021","journal-title":"Clin Exp Allergy."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1111\/jdv.17549","article-title":"Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine","volume":"35","author":"Smola","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2021.1375","article-title":"Necessity of 2 doses of the pfizer and moderna COVID-19 vaccines","volume":"325","author":"Livingston","year":"2021","journal-title":"Jama."},{"key":"B29","unstructured":"Moderna COVID-19 Vaccine EUA Fact Sheet"},{"key":"B30","unstructured":"Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.825164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T23:45:21Z","timestamp":1643759121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.825164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":30,"alternative-id":["10.3389\/falgy.2022.825164"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2022.825164","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/CP6GX2","asserted-by":"object"}]},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"article-number":"825164"}}